
GV participated in a series C round for the fertility and gynaecology services provider at a $612m valuation, doubling its overall funding.
Waste management software provider Recycle Track Systems bagged $35m in a Citi-led series C round while muscular dystrophy drug developer Vita Therapeutics completed a $32m series A.
The AstraZeneca, Sinopharm and Eli Lilly-backed oncology drug developer has revealed its intention to go public in a Hong Kong IPO that could reportedly fetch $250m.
GV notched up an exit as cancer therapy developer Monte Rosa Therapeutics priced an upsized initial public offering at the top of its range.
DNA Capital has returned to lead a $59.5m round for the Qualcomm Ventures-backed digital prescription startup.
BeiGene helped mRNA therapeutics developer Strand Therapeutics raise $52m while the Afterpay-backed AP Ventures led logistics provider Sendle's $35m series C round.
Novo and Orlando Health helped the haemodialysis technology provider increase its overall funding to $350m since it was spun off by IMI.
Long-term investor Boston Scientific is paying $295m upfront for the 73% of the ablation technology developer it does not own.
Sanofi Ventures co-led replacement therapy developer Glycomine's latest round, which included Novo, Asahi Kasei Pharma Ventures and Chiesi Ventures.
Alexandria Venture Investments backed precision immunology therapeutics developer ImmuneID in the round, which was led by venture capital firm Alta Partners.